New clinical trial data show an extended-release version of a Parkinson’s disease drug could provide more stable relief for patients with the movement disorder.
Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.
